Outcome of Botulinum Toxin‐A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study

The Prostate ◽  
2019 ◽  
Vol 79 (11) ◽  
pp. 1221-1225
Author(s):  
Ayman S. Moussa ◽  
Ahmed M. Ragheb ◽  
Ahmed M. Abdelbary ◽  
Rabie M. Ibrahim ◽  
Mahmoud S. El Adawy ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Multicenter Study ◽  
Lower Urinary Tract ◽  
Botulinum Toxin A ◽  
Prostatic Hyperplasia ◽  
Prospective Multicenter Study ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?

Toxins ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 547 ◽  
Author(s):  
Bing-Juin Chiang ◽  
Hann-Chorng Kuo ◽  
Chun-Hou Liao
Keyword(s):  
Botulinum Toxin ◽  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Botulinum Toxin A ◽  
Prostatic Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Prostatic Inflammation ◽  
Lower Urinary

Patients with benign prostatic hyperplasia (BPH) can exhibit various lower urinary tract symptoms (LUTS) owing to bladder outlet obstruction (BOO), prostatic inflammation, and bladder response to BOO. The pathogenesis of BPH involves an imbalance of internal hormones and chronic prostatic inflammation, possibly triggered by prostatic infection, autoimmune responses, neurogenic inflammation, oxidative stress, and autonomic dysfunction. Botulinum toxin A (BoNT-A) is well recognized for its ability to block acetylcholine release at the neuromuscular junction by cleaving synaptosomal-associated proteins. Although current large clinical trials have shown no clinical benefits of BoNT-A for the management of LUTS due to BPH, BoNT-A has demonstrated beneficial effects in certain subsets of BPH patients with LUTS, especially in males with concomitant chronic prostatitis/chronic pelvic pain syndrome and smaller prostate. We conducted a review of published literature in Pubmed, using Botulinum toxin, BPH, BOO, inflammation, LUTS, and prostatitis as the key words. This article reviewed the mechanisms of BPH pathogenesis and anti-inflammatory effects of BoNT-A. The results suggested that to achieve effectiveness, the treatment of BPH with BoNT-A should be tailored according to more detailed clinical information and reliable biomarkers.

Sign in / Sign up

Export Citation Format

Share Document